Clinical Trial Update: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase II study evaluating eribulin mesylate in combination with trastuzumab and pertuzumab for HER2-positive breast cancer was terminated, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-12-05